Yiqi Gubiao Pill for tuberculosis-associated obstructive pulmonary disease: protocol for a double-blind randomized controlled trial.

ABSTRACT:

Background

Tuberculosis-associated obstructive pulmonary disease (TOPD), recognized as a high-morbidity respiratory condition in most countries, presents significant clinical challenges in differential diagnosis and comorbidity management, while substantially elevating all-cause mortality risk. Preclinical investigations of Yiqi Gubiao Pill (National Patent ZL201410536529.5) have demonstrated multi-target therapeutic efficacy, including cough suppression, bronchospasm alleviation, sputum expectoration facilitation, and disease progression retardation. This randomized controlled trial aims to systematically assess Yiqi Gubiao's therapeutic and evaluate its safety.

Methods

We will implement a prospective double-blind randomized controlled trial utilizing 1:1 allocation ratio,

SUBMITTER: Dai J 

PROVIDER: S-EPMC12540363 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature